Decibel Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DBTX research report →
Companywww.decibeltx.com
Decibel Therapeutics, Inc. , a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin.
- CEO
- Laurence E. Reid
- IPO
- 2021
- Employees
- 68
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $123.37M
- P/E
- -1.95
- P/S
- 0.00
- P/B
- 1.50
- EV/EBITDA
- -1.71
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -56.38%
- ROIC
- -61.19%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-63,005,000 · -21.58%
- EPS
- $-2.52 · -5.88%
- Op Income
- $-63,957,000
- FCF YoY
- -30.68%
Performance & Tape
- 52W High
- $5.40
- 52W Low
- $1.61
- 50D MA
- $4.29
- 200D MA
- $3.62
- Beta
- -0.40
- Avg Volume
- 214.74K
Get TickerSpark's AI analysis on DBTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 25, 23 | Trask Anna | sell | 106,864 |
| Sep 25, 23 | Trask Anna | sell | 45,000 |
| Sep 25, 23 | Trask Anna | sell | 52,500 |
| Sep 25, 23 | Trask Anna | sell | 137,302 |
| Sep 25, 23 | Carson William H. | sell | 10,000 |
| Sep 25, 23 | Carson William H. | sell | 5,000 |
| Sep 25, 23 | Carson William H. | sell | 5,000 |
| Sep 25, 23 | Carson William H. | sell | 20,000 |
| Sep 25, 23 | Lee John Jui-Jen | sell | 147,144 |
| Sep 25, 23 | Lee John Jui-Jen | sell | 45,000 |
Our DBTX Coverage
We haven't published any research on DBTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DBTX Report →